RECOMBINATE 500 IU

Country: Израел

Језик: Енглески

Извор: Ministry of Health

Активни састојак:

COAGULATION FACTOR VIII RECOMBINANT 500 IU/VIAL

Доступно од:

TEVA MEDICAL MARKETING LTD.

АТЦ код:

B02BD05

Фармацеутски облик:

POWDER FOR SOLUTION FOR INJECTION

Пут администрације:

I.V

Произведен од:

BAXTER S.A., BELGIUM

Терапеутска група:

COAGULATION FACTOR VII

Терапеутске индикације:

The use of Recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Recombinate is also indicated in the perioperative management of patients with haemophilia A. Recombinate is appropriate for use in children of all ages including the newborn. (Safety and efficacy studies have been performed in both previously treated and previously untreated children). The product in not suitable for the treatment of von Willebrand's disease.

Датум одобрења:

2010-07-01